Emerging Treatments in Cystic Fibrosis

@article{Jones2012EmergingTI,
  title={Emerging Treatments in Cystic Fibrosis},
  author={A. Jones and J. Helm},
  journal={Drugs},
  year={2012},
  volume={69},
  pages={1903-1910}
}
  • A. Jones, J. Helm
  • Published 2012
  • Medicine
  • Drugs
  • There are a number of potential drugs for the treatment of cystic fibrosis (CF) currently undergoing clinical studies. A number of antibacterials formulated for delivery by inhalation are at various stages of study; these include dry-powder inhaler versions of colistin, tobramycin and ciprofloxacin, and formulations of azteonam, amikacin, levofloxacin, ciprofloxacin and fosfomycin/tobramycin for nebulization. Clinical trials of anti-inflammatory agents, including glutathione, phosphodiesterase… CONTINUE READING
    96 Citations
    New and Emerging Treatments for Cystic Fibrosis
    • 13
    Cystic fibrosis therapeutics: the road ahead.
    • 79
    Inhalation of macrolides: a novel approach to treatment of pulmonary infections.
    • 10
    Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine
    • 15
    THERAPEUTIC DEVELOPMENT FOR CYSTIC FIBROSIS
    • 1
    • PDF

    References

    SHOWING 1-10 OF 61 REFERENCES
    A phase I trial of intranasal Moli1901 for cystic fibrosis.
    • 72
    • PDF
    Safety and Efficacy of Recombinant Alpha1‐Antitrypsin Therapy in Cystic Fibrosis
    • 88
    Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial
    • 473
    • Highly Influential
    • PDF
    Inhalation of Moli1901 in patients with cystic fibrosis.
    • 114
    Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    • 863
    • Highly Influential
    • PDF
    Macrolide antibiotics for cystic fibrosis.
    • 168
    Clinical trials in cystic fibrosis.
    • 45
    • Highly Influential
    • PDF
    Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    • 1,053
    Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    • 63
    • PDF